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Introduction: Psoriasis and psoriatic arthritis (PsA) increase cardiovascular disease (CVD) risk, but surrogate markers
for CVD in these disorders are inadequate. Because the presence of sacroiliitis may portend more severe PsA, we
hypothesized that sacroiliitis defined by computed tomography (CT) would be associated with increased vascular
inflammation defined by 18-fluorodeoxyglucose-positron emission tomography/computed tomography
(FDG-PET/CT), which is an established measure of CVD.
Methods: Participants (n = 65) underwent whole-body FDG-PET/CT. Metabolic activity of the aorta was measured
using the maximal standardized uptake value (SUVmax), a measure of atherosclerotic plaque activity. The primary
outcome was aortic vascular inflammation. Linear regression (with β-coefficients (β) and P-values reported for PsA
and sacroiliitis) was used to adjust for CVD risk factors to determine associations of PsA or sacroiliitis with vascular
inflammation. Likelihood ratio testing was performed to evaluate the contribution of sacroiliitis to vascular disease
estimation compared to the effects of PsA and traditional CVD risk factors.
Results: Vascular inflammation (measured as SUVmax) was greater (P < 0.001) in patients with sacroiliitis (mean ± SD =
7.33 ± 2.09) defined by CT compared to those without sacroiliitis (6.39 ± 1.49, P = 0.038). There were associations
between PsA and aortic inflammation (β = 0.124, P < 0.001) and between sacroiliitis and aortic inflammation (β = 0.270,
P < 0.001) after adjusting for CVD risk factors. Sacroiliitis predicted vascular inflammation beyond PsA and CVD risk
factors (χ2 = 124.6, P < 0.001).
Conclusions: Sacroiliitis is associated with increased vascular inflammation detected by FDG-PET/CT, suggesting that
sacroiliac joint disease may identify patients at greater risk for CVD. Large, ongoing prospective studies are required to
confirm these findings.* Correspondence: nehal.mehta@nih.gov
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Systemic inflammatory disorders, including psoriasis (Pso)
[1-3] and psoriatic arthritis (PsA) [3], increase incident
cardiovascular events beyond traditional cardiovascular
disease (CVD) risk factors [4]. Understanding of this ele-
vated risk has been hampered by the lack of suitable clin-
ical biomarkers linking systemic inflammation and CVD.
Prevention of increased CVD morbidity and mortality in
Pso and PsA requires identification of those patients at
greatest risk for these diseases prior to the development of
overt symptoms. 18-Fluorodeoxyglucose-positron emis-
sion tomography/computed tomography (FDG-PET/CT)
is an imaging modality that may provide this capability, as
it delineates enhanced metabolic activity in tissues in vivo,
including vascular inflammation [5-9]. Importantly, vascu-
lar inflammation seen on FDG-PET/CT scans has been
shown to precede the development of atherosclerotic dis-
ease [10] and to predict future cardiovascular events
[11,12]. Our prior investigations in which we utilized FDG-
PET/CT have shown increased inflammation in multiple
tissues, including the skin, liver, joints, entheses and vascu-
lature in Pso and PsA patients compared to healthy con-
trols [6,13,14]. We have also previously demonstrated
relationships between FDG-PET/CT imaging measure-
ments and both known and novel CVD biomarkers,
thereby validating FDG-PET/CT findings as reliable predic-
tors of outcome [15]. However, these pilot studies were
underpowered to adequately assess for PsA or axial disease.
Sacroiliitis is a characteristic feature of the spondyloar-
thropathies, including PsA [16]. Imaging of patients with
sacroiliitis is an element of the current classification cri-
teria for these disorders [17,18]. Imaging of the sacroiliac
(SI) joints by CT scan is one modality that is accepted
for making the diagnosis of sacroiliitis [19-27]. Further,
the presence of sacroiliitis may identify a PsA subgroup
at risk for more severe arthropathy [28,29]. Greater in-
flammatory burden imposed by severe Pso [1,30,31] and
the presence of PsA [32,33] increases the risk of CVD.
Thus, we hypothesized that PsA and sacroiliitis diag-
nosed by CT scan would be associated with increased
vascular inflammation by FDG-PET/CT scan in a well-
characterized population of Pso patients with versus
without a diagnosis of PsA. Here we present a consecu-
tive sample of 65 patients who completed baseline stud-
ies in the Psoriasis Atherosclerosis and Cardiometabolic
Disease Initiative (PACI; ClinicalTrials.gov Identifier:
NCT01778569). A major aim of this prospective, longi-
tudinal study is to identify incident biomarkers of vascu-
lar and metabolic disease in Pso and PsA.
Methods
Study population
Whole-body FDG-PET/CT was performed in a consecu-
tive sample of patients (n = 65) ages 18 to 70 years withPso alone (n = 38) or with both Pso and PsA (n = 27).
Our study population was recruited to the National In-
stitutes of Health (NIH) Clinical Center using flyers and
pamphlets distributed at dermatology clinics and via
academic dermatological societies, as well as by using
web-driven tools such as [34] and [35]. Diagnostic con-
firmation of plaque Pso and assessment of body surface
area (BSA) and Psoriasis Area and Severity Index (PASI)
were performed by a dermatologist. PsA classifications
were confirmed by a rheumatologist according to the
ClASsification criteria for Psoriatic ARthritis (CASPAR)
[36]. A rheumatologist did the swollen and tender joint
counts using the American College of Rheumatology 66/
68 joint count core set [37]. Clinical assessment of enthe-
sitis (by Leeds Enthesitis Index score [38]), dactylitis (by
number of dactylitic digits) and inflammatory back pain
(according to Assessment of SpondyloArthritis inter-
national Society (ASAS) criteria [39] and Calin criteria
[40]) was also performed by a rheumatologist. Exclusion
criteria included disease states that can increase systemic
or vascular inflammation, such as known history of CVD,
uncontrolled hypertension (defined as systolic blood pres-
sure (SBP) >180 mmHg or diastolic blood pressure (DBP)
>95 mmHg), nondermatologic malignant disease within
the past 5 years, positive HIV status, major surgery within
the past 3 months and history of intravenous drug use or
active infection within the preceding 72 hours. Hyperten-
sion was defined as SBP >140 mmHg, DBP >90 mmHg
and/or currently on antihypertensive therapy. Hyper-
lipidemia was defined as total cholesterol >200 mg/dl,
low-density lipoprotein (LDL) ≥160 mg/dl, high-density
lipoprotein (HDL) <40 mg/dl, triglycerides >150 mg/dl
and/or use of a cholesterol-lowering agent. Diabetes was
defined as fasting glucose ≥126 mg/dl, hemoglobin A1c
≥6.5% and/or taking antidiabetic therapy.
FDG-PET/CT
Whole-body FDG-PET/CT scans were obtained using a
standardized published protocol [13]. Following an over-
night fast, patients were imaged 60 minutes after receiv-
ing an injection of 370 MBq of 18-FDG. Images were
acquired in three-dimensional mode using a Siemens
Biograph TruePoint PET/CT scanner (Siemens Health-
care, Erlangen, Germany). FDG-PET/CT images were
reviewed by a reader, blinded to all patient characteris-
tics, using dedicated PET/CT image analysis software
(Extended Brilliance Workstation (EBW); Philips Health-
care, Amsterdam, the Netherlands). FDG uptake in the
thoracic and abdominal aorta was quantified using pub-
lished methods [6]. Briefly, circular two-dimensional re-
gions of interest (ROI) circumscribing the external aortic
contour were drawn on serial contiguous transaxial 4-
mm sections from the level of the aortic root to the iliac
bifurcation (Figure 1). Each axial segment provided two
Figure 1 18-fluorodeoxyglucose-positron emission tomography/computed tomography delineates vascular inflammation. Images
shown are representative computed tomography (CT) (left panels), 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) (center
panels) and fused FDG-PET/CT transaxial (right panels) scans from a patient with an unaffected aortic vasculature (upper panel) and one with an
inflamed aortic vasculature (lower panel). Regions of interest outlining the ascending thoracic aorta are depicted in yellow in all images. A
ring-shaped focus of increased metabolic activity in the aortic wall is also shown (blue arrows in FDG/PET and fused FDG-PET/CT images).
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imum standardized uptake (SUVmean and SUVmax, re-
spectively). SUVmean and SUVmax values were determined
using commercial software (EBW) for each successive
slice. SUVmax values were averaged over three consecutive
slices to measure the most inflamed aortic region in each
patient. A nuclear medicine specialist independently eval-
uated FDG-PET/CT scans for imaging quality, radiotracer
biodistribution, uptake time and clinical findings.
Imaging evaluation for sacroiliitis
Sacroiliitis diagnosed by CT scan was evaluated using
guidelines developed by Geijer and colleagues [41].
Sacroiliitis grade was classified as “no disease” (that is,
radiographically normal, degenerative change evident or
some blurring of the joint margins), “suspected disease”
(that is, unilateral sclerosis with some erosion) or “defin-
ite disease” (that is, bilateral sclerosis with erosion, or
unilateral or bilateral sclerosis with severe erosion and a
change in joint space with or without partial ankylosis,
or complete ankylosis). Both axial and coronal CT scan
orientations were examined. Sclerosis, erosions, anky-
losis and/or joint space changes had to be evident on at
least two consecutive slices to be deemed significant.
Serum factor determination
Fasting levels of total, HDL and LDL cholesterol, triglyc-
erides, glucose, erythrocyte sedimentation rate (ESR)
and high-sensitivity C-reactive protein (hsCRP) were
measured in a clinical laboratory.
Statistical analysis
Normality was assessed by skewness and kurtosis. Nor-
mally distributed continuous variables were compared
using Student’s t-test. Continuous variables lacking a nor-
mal distribution were compared using Mann–Whitney Utest. Dichotomous variable comparisons were performed
using Fisher’s exact test. Student’s t-test was employed to
compare FDG-PET/CT measures (SUVmax) of aortic in-
flammation between Pso and PsA groups and between pa-
tients with or without CT evidence of sacroiliitis. Only
those patients with definitive disease defined by CT were
considered to have sacroiliitis for all analyses. Patients not
meeting the CASPAR criteria [36] for PsA were classified
as having PSO. Relationships between variables were de-
termined using Spearman correlation analysis and are
reported as Spearman ρ (r) values. Multivariate linear re-
gression analysis was performed using aortic SUVmax as
the dependent variable and CVD risk factors (age, sex,
body mass index (BMI), diabetes, hypertension, dyslipid-
emia and pack-years of tobacco use) and either PsA or
sacroiliitis evident by CT scan as independent variables, as
reported. Sex, diabetes, hypertension, dyslipidemia, PsA
and sacroiliitis were adjusted for as dichotomous variables
in the models; all other variables were continuous. Similar
findings were revealed in independent analyses designat-
ing sex, PsA and sacroiliitis as dichotomous variables and
age, BMI, fasting glucose, SBP, LDL cholesterol, tobacco
use and aortic SUVmax as continuous variables. Both
fixed- and random-effects regression analyses were per-
formed on each model to accommodate within-patient
correlation of SUVmax values [13]. Because the magnitude
of the estimates of PsA and sacroiliitis using vascular mea-
sures did not differ when fixed- and random-effects re-
gression analyses were performed, we report β-coefficients
(β) and P-values for the fixed effects models after adjust-
ment for CVD risk factors. Further, we examined the out-
come variable aortic SUVmax in separate multivariate
linear regression models using either slice-by-slice SUVmax
measures or collapsed individual patient values. The mag-
nitude of the effect of the covariates on aortic SUVmax was
similar in both models; hence, we report the slice-by-slice
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strating that aortic SUV increased 0.1 U (SD ±0.1) per
decade of life, we considered this to be a clinically relevant
difference. Therefore, with these assumptions, our sample
size (n = 65) provided >90% power to detect a difference
of 0.1 in aortic vascular inflammation by the presence or
absence of SI inflammation. Likelihood-ratio testing was
performed in nested Tobit models to determine the incre-
mental value of sacroiliitis to CVD estimation above and
beyond PsA and traditional CVD risk factors. STATA 12
statistical software (StataCorp, College Station, TX, USA)
was utilized for all analyses. Study approval was obtained
from the National Heart, Lung, and Blood Institute Insti-
tutional Review Board in accordance with the Declaration
of Helsinki. All guidelines for GCP and those set forth by
the NIH Radiation Safety Commission and in the Belmont
Report (National Commission for the Protection of Hu-
man Subjects of Biomedical and Behavioral Research)
were followed. All study participants provided written in-
formed consent.
Results
Patient demographics, disease assessments and CVD risk
factors
Patient characteristics (n = 65) and laboratory measure-
ments are presented in Table 1 for the whole sample
and for the Pso (n = 38) and PsA (n = 27) subgroups.
Our study population had a median age of 53 years, was
nearly equally distributed by sex (54% male) and had
moderate skin disease on average (mean BSA = 9.2,
mean PASI score = 7.8) (Table 1). The proportion who
had PsA was 41%. Median skin disease duration was 20
years for both the Pso and PsA subgroups, and the me-
dian duration of joint disease was 10 years in PsA pa-
tients (Table 1). One patient met both the Calin and
ASAS criteria for inflammatory back pain. This patient
was classified as having Pso, however, due to not meet-
ing the CASPAR criteria for PsA and having CT images
showing advanced degenerative and postsurgical changes
in the spine without evidence of spondylitis or sacroilii-
tis. Two additional patients were definitively diagnosed
with sacroiliitis by CT without evidence of inflammatory
back pain, SI tenderness to palpation or provocative ma-
neuvers, arthritis, enthesitis or dactylitis. Because both
of those two patients met the CASPAR criteria for PsA,
they were classified as having asymptomatic axial PsA.
Sacroiliitis diagnosed by CT scan was confirmed in 44%
of PsA patients (Table 1).
We also assessed Medication use and cardiovascular
and metabolic comorbidities in our study population
(Table 1). Many patients (37%) were using topical steroids,
whereas systemic steroid therapy and phototherapy were
rare (Table 1). Disease-modifying antirheumatic drug
(DMARD) treatment was uncommon and was notstatistically different (P = 0.224) between the PsA (15%)
and Pso (5%) groups (Table 1). Biologic therapy was more
common (P = 0.022) in PsA patients (56%) than in Pso pa-
tients (26%). Traditional CVD risk factors, including
hypertension, dyslipidemia, diabetes mellitus and tobacco
use, were prevalent in our study population, as was treat-
ment for these disorders. Presence and treatment of CVD
risk factors were not statistically different between the Pso
and PsA subgroups (Table 1).
Vascular inflammation measured by FDG-PET/CT is
greater in patients with sacroiliitis defined by CT
We utilized FDG-PET/CT to examine vascular inflam-
mation, as defined by aortic SUVmax, in our study popu-
lation. Mean (SD) SUVmax values for the aortic region
demonstrating the highest vascular inflammation in
three contiguous slices were numerically, but not statis-
tically, greater (P = 0.536) in PsA patients (6.72 ± 1.92)
compared to Pso patients (6.46 ± 1.43) (Table 2). Be-
cause sacroiliitis has been shown to signify worse ar-
thropathy in PsA [28,29], we hypothesized that the
greater inflammatory state in patients with sacroiliitis
may lead to increased vascular inflammation visualized
by FDG-PET/CT. Indeed, mean aortic SUVmax measures
(Table 2) were significantly greater (P = 0.038) in pa-
tients with CT evidence of sacroiliitis (7.33 ± 2.09) com-
pared to those without SI joint disease (6.39 ± 1.49).
Further, aortic vascular inflammation was greatest in
those demonstrating the highest grade (definitive disease)
of sacroiliitis by CT scan (Additional file 1: Table S1).
Sacroiliitis defined by CT scan correlates with vascular
inflammation evaluated by FDG-PET/CT above and
beyond CVD risk factors
To determine covariates of vascular inflammation by
highest atherosclerotic plaque activity within our cohort,
individual Spearman correlation analyses were performed
between aortic SUVmax and clinical, laboratory and im-
aging parameters in the total population and in the Pso
and PsA subgroups (Additional file 2: Table S2). In un-
adjusted analyses of the total study population (Additional
file 2: Table S2), aortic SUVmax was significantly related to
traditional CVD risk factors, including age (r = 0.406, P <
0.001), sex (r = 0.146, P < 0.001), BMI (r = 0.507, P <
0.001), hypertension (r = 0.204, P < 0.001), diabetes (r =
0.186, P < 0.001), dyslipidemia (r = 0.226, P < 0.001) and
tobacco use (r = −0.021, P = 0.01). Sacroiliitis (r = 0.213,
P < 0.001) was more strongly related to vascular inflam-
mation than were the relationships between vascular in-
flammation and psoriatic arthritis (r = 0.033, P < 0.001),
PASI score (r = 0.001, P = 0.919), ESR (r = 0.061, P <
0.001) or hsCRP (r = −0.005, P = 0.513) in the total sam-
ple. In general, aortic SUVmax and CVD risk factors were
more strongly related in PsA than in Pso patients
Table 1 Patient characteristicsa
Characteristics All (n = 65) Pso (n = 38) PsA (n = 27) P-value
Age, yr 53 (41 to 61) 54 (41 to 65) 52 (41 to 59) 0.526
Males, n (%) 35 (54) 21 (55) 14 (52) 0.806
Psoriasis disease duration, yr 20 (9 to 32) 20 (8 to 35) 20 (10 to 31) 0.931
Body surface area score, mean (SD) 9.2 (16) 8.1 (13.7) 10.8 (19.0) 0.827
PASI score, mean (SD) 7.8 (9.3) 7.3 (7.9) 8.7 (11.2) 0.967
Psoriatic arthritis, n (%) 27 (41) – – –
Psoriatic arthritis disease duration, yr – – 10 (4 to 15.5) –
Tender joint count (0 to 68), mean (SD) – – 8.9 (10.8) –
Swollen joint count (0 to 66), mean (SD) – – 5.4 (9.0) –
ASAS inflammatory back pain criteria met, n (%) – – 4 (17) –
Calin inflammatory back pain criteria met, n (%) – – 5 (21) –
Enthesitis score (0 to 6), mean (SD) – – 1.0 (1.5) –
Dactylitis count (0 to 20), mean (SD) – – 1.4 (3.8) –
Sacroiliac disease diagnosed by CT, n (%) – – 12 (44) –
DMARD therapy, n (%) 6 (9) 2 (5) 4 (15) 0.224
Biologic therapy, n (%) 25 (39) 10 (26) 15 (56) 0.022
DMARD and biologic therapy, n (%) 4 (6) 2 (5) 2 (7) 1.000
NSAID therapy, n (%) 15 (23) 3 (8) 12 (44) 0.001
Phototherapy, n (%) 3 (5) 1 (3) 2 (7) 0.565
Topical steroid therapy, n (%) 24 (37) 14 (37) 10 (37) 1.000
Systemic steroid therapy, n (%) 1 (2) 0 (0) 1 (4) 0.415
Diabetes mellitus, n (%) 7 (11) 4 (11) 3 (11) 1.000
Hypertension, n (%) 21 (32) 13 (34) 8 (30) 0.791
Dyslipidemia, n (%) 44 (68) 29 (76) 15 (56) 0.108
Current tobacco use, n (%) 6 (9) 3 (8) 3 (11) 1.000
Former tobacco use, n (%) 18 (28) 12 (32) 6 (22) 0.684
Pack-years tobacco use 0 (0 to 4.5) 0 (0 to 5) 0 (0 to 0.8) 0.590
Diabetes mellitus therapy, n (%) 4 (6) 2 (5) 2 (7) 1.000
Antihypertensive therapy, n (%) 12 (19) 7 (18) 5 (19) 1.000
Hyperlipidemia therapy, n (%) 24 (37) 15 (39) 9 (33) 0.795
Body mass index, kg/m2 29 (25.9 to 32.3) 29 (24.9 to 32.4) 29 (26.7 to 32) 0.572
Systolic blood pressure, mmHg 125 (116 to 135) 129 (120 to 135) 122 (115 to 133) 0.266
Diastolic blood pressure, mmHg 72 (65 to 78) 71 (66 to 78) 74 (63 to 79) 0.719
Fasting blood glucose, mg/dl 94 (89 to 104) 94 (89 to 104) 94 (89 to 107) 0.895
Total cholesterol, mg/dl 184 (158 to 203) 185 (158 to 207) 172 (157 to 201) 0.910
Triglycerides, mg/dl 108 (84 to 137) 109 (84 to 149) 101 (81 to 131) 0.604
High-density lipoprotein cholesterol, mg/dl 52 (42 to 63) 52 (42 to 69) 51 (47 to 59) 0.947
Low-density lipoprotein cholesterol, mg/dl 96 (80 to 125) 95 (80 to 125) 98 (78 to 125) 0.851
Erythrocyte sedimentation rate, mm/hr 8 (5 to 13) 8 (4 to 10) 12 (5 to 18) 0.097
High-sensitivity C-reactive protein, g/dl 1.7 (0.7 to 4.2) 1.2 (0.7 to 3.1) 3.0 (0.8 to 8) 0.221
aASAS, Assessment of SpondyloArthritis international Society; DMARD, Disease-modifying antirheumatic drug; IQR, Interquartile range; NSAID, Nonsteroidal
anti-inflammatory drug; PASI, Psoriasis Area and Severity Index; PsA, Psoriatic arthritis; Pso, Psoriasis. Data are reported as median (IQR) unless indicated otherwise.
DMARD therapy denotes methotrexate use, except for 1 patient who was taking both methotrexate and hydroxychloroquine. Biologic therapy indicates active TNF
antagonist or anti-IL-12/23 receptor use except for one patient who was treated with abatacept for psoriatic arthritis. Reported P-values are for comparisons of
Pso vs. PsA using Fisher’s exact tests for categorical variables, Mann-Whitney U tests for non-normally distributed continuous variables, and Student’s t-tests for
normally distributed continuous variables. P < 0.05 was set as the significance level.
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Table 2 Vascular inflammation is increased in patients
with sacroiliitisa
Pso (n = 38) PsA (n = 27)
Mean ± SD Mean ± SD P-value





Mean ± SD Mean ± SD P-value
Aortic SUVmax 6.39 ± 1.49 7.33 ± 2.09 0.038
aCT, Computed tomography; PsA, Psoriatic arthritis; Pso, Psoriasis; SUVmax,
Maximum standardized uptake value. Data are reported as mean ± SD of the
greatest aortic SUVmax region (three consecutive slices) for each patient. Indicated
P-values (P < 0.05 deemed significant) are for Student’s t-test comparisons of
either Pso vs PsA or absence vs presence of sacroiliitis by CT scan.
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performed using SUVmean as the outcome variable, similar
results were obtained. The aortic SUVmax data are re-
ported, as this measurement indicates the region of most
intense vascular inflammation.
In multivariate regression analyses (Table 3), sacroilii-
tis remained highly associated with vascular inflamma-
tion, even after adjusting for age, sex and BMI (β =
0.268, P < 0.001) and with additional adjustment for
hypertension, dyslipidemia, diabetes and tobacco use (β =
0.270, P < 0.001). PsA was also associated with vascular in-
flammation (Table 3) in both partially adjusted (age, sex
and BMI; β = 0.117, P < 0.001) and fully adjusted models
(age, sex, BMI, hypertension, dyslipidemia, diabetes and
tobacco; β = 0.124, P < 0.001). To obtain a crude estimate
for systemic inflammatory burden, multivariate regression
analyses were further adjusted for ESR and hsCRP levels.
Addition of ESR (β = 0.268, P < 0.001) or hsCRP (β =
0.303, P < 0.001) as independent variables did not affect
the relationship between sacroiliitis and vascular inflam-
mation in fully adjusted models (Additional file 3: Table
S3). PsA and aortic SUVmax also remained significantly
related after adding ESR (β = 0.110, P < 0.001) or hsCRP
(β = 0.133, P < 0.001) into fully adjusted models. TheTable 3 Sacroiliitis and psoriatic arthritis are positively
related to vascular inflammation even after adjustment
for CVD risk factorsa
Regression factors Age, sex and BMI Age, sex, BMI, HTN,
DL, DM, Tob
Sacroiliitis 0.268 (P < 0.001) 0.270 (P < 0.001)
Psoriatic arthritis 0.117 (P < 0.001) 0.124 (P < 0.001)
aMultivariate linear regression analyses were performed using aortic maximum
standardized uptake (SUVmax) as the dependent variable. Independent
variables included in the model were (1) age, sex, body mass index (BMI) and
either sacroiliitis (row 1, left column) or psoriatic arthritis (row 2, left column)
or (2) age, sex, BMI, hypertension (HTN), dyslipidemia (DL), diabetes mellitus
(DM), tobacco use (Tob) and either sacroiliitis (row 1, right column) or psoriatic
arthritis (row 2, right column). β-coefficients (P-values) are reported for the effects
of sacroiliitis or psoriatic arthritis on vascular inflammation (aortic SUVmax) after
adjustment for cardiovascular disease risk factors (age, sex, BMI, HTN, DL, DM and
Tob). P-values <0.05 were considered significant.contribution of sacroiliitis to aortic SUVmax estimation be-
yond PsA and/or traditional CVD risk factors was deter-
mined using likelihood-ratio testing (Table 4). Sacroiliitis
defined by CT scan predicted vascular inflammation
(Table 4) above and beyond PsA in unadjusted models
(χ2 = 374.6, P < 0.001) and beyond PsA and CVD risk
factors in partially adjusted (χ2 = 132.8, P < 0.001) and
fully adjusted models (χ2 = 124.6, P < 0.001). Together,
these findings suggest that sacroiliitis defined by CT scan
may independently confer risk of higher vascular inflam-
mation in patients with Pso and PsA.
Discussion
To our knowledge, this report is the first to link sacroi-
liitis defined by CT scan and vascular inflammation in
Pso and PsA, an association that persisted after adjust-
ment for traditional CVD risk factors. Aortic inflamma-
tion measured by FDG-PET/CT was found to be greater
in patients with evidence of sacroiliitis compared to
those without SI joint disease. We were able to deter-
mine that sacroiliitis impacted vascular inflammation in
a dose-dependent fashion, as aortic SUVmax values were
greatest in those with sacroiliitis definitively diagnosed
by CT scan compared to those with no disease or sus-
pected disease. Further, vascular inflammation measured
by FDG-PET/CT correlated with sacroiliitis in both un-
adjusted models and in models adjusted for CVD risk
factors and markers of systemic inflammation. Import-
antly, sacroiliitis was a strong predictor of CVD above
and beyond PsA and traditional risk factors. Taken to-
gether, these findings suggest that sacroiliitis not only
may identify those at risk for more severe joint disease
[28,29] but may also be an indicator of increased suscep-
tibility to CVD.
Identification of sacroiliitis as a correlate of CVD holds
tremendous clinical promise since it is a characteristic
feature of PsA [17,18] and can readily be screened for in
this disorder. Since use of FDG-PET/CT for CVD risk
stratification in Pso and PsA is unlikely to extend be-
yond the research realm in the foreseeable future,Table 4 Sacroiliitis predicts vascular inflammation
beyond psoriatic arthritis and CVD risk factorsa
Model Aortic SUVmax χ
2 (P-value)
Unadjusted 374.6 (<0.001)
Partially adjusted 132.8 (<0.001)
Fully adjusted 124.6 (<0.001)
aLikelihood ratio testing was applied in nested Tobit models to assess the
incremental value of sacroiliitis in predicting aortic vascular inflammation. The
outcome variable was aortic maximum standardized uptake (SUVmax). Independent
variables in the different models were as follows: psoriatic arthritis (unadjusted);
age, sex, BMI and psoriatic arthritis (partially adjusted); and age, sex, BMI,
hypertension, dyslipidemia, diabetes, tobacco use and psoriatic arthritis (fully
adjusted). χ2 values are reported for each model. P-values < 0.05 were considered
significant.
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risk of CVD in these populations. Future studies should
extend our findings by examining the relationship be-
tween sacroiliitis and CVD in other spondyloarthropa-
thies, and by determining whether active inflammation in
the SI joint confers even greater risk for CVD. Whether
sacroiliitis also relates to other psoriatic comorbidities is a
subject of ongoing investigation in our cohort.
It has been suggested that higher inflammatory burden
imparts increased CVD risk in the systemic inflamma-
tory diseases [4]. Indeed, greater skin disease severity
has been linked to increased CVD mortality in Pso
[1,30,31,42], and this observation has been further sup-
ported by data demonstrating cardiometabolic and CVD
modulation in lesional psoriatic skin [43,44]. Further-
more, PsA has generally been considered to represent a
heightened inflammatory state compared to Pso alone
[3], and thus PsA may confer an elevated risk of CVD-
associated morbidity and mortality [45]. Although epide-
miologic studies have yielded conflicting data regarding
all-cause mortality risk in PsA [42,46-51], the results of
several studies demonstrate that PsA increases CVD-
attributable mortality compared to the general popula-
tion [30,42,52] and to Pso patients [32,33,42,53]. Our
findings suggest that screening for particular features of
Pso and PsA rather than global measures of systemic in-
flammation may be a more viable strategy for identifying
patients at increased risk for CVD. In support of this no-
tion, our results presented here demonstrate that sacroi-
liitis, as defined by CT scan, and vascular inflammation
were associated with PsA above and beyond traditional
CVD risk factors and independent of levels of systemic
inflammatory markers (ESR and hsCRP). Thus, sacroilii-
tis may be a potentially useful metric of CVD beyond
crude measures of systemic inflammation.
We acknowledge that this study has certain limitations
and that additional research is required to corroborate
and extend our findings. The modest sample size and
single-center study design could affect the generalizability
of the results. Further, FDG-PET/CT may not be suitable
for widespread adoption, owing to its limited availability
for nonmalignant conditions and its mild radiation expos-
ure. In addition, evaluation of sacroiliitis by CT scan may
overestimate the frequency of patients with sacroiliitis
[41,54], which could have impacted our results. Although
analyses were adjusted for CVD risk factors and markers
of systemic inflammation, other potential confounding
variables, including Pso and PsA disease duration as well
as disease activity and therapy, may have decreased the
magnitude of the observed associations. Our study design
was generally inclusive in order to allow us to understand
the impact of Pso and PsA on vascular inflammation
across a wide range of disease manifestations and therap-
ies (that is, in a setting closer to the “real world”). Thus,the relationship between sacroiliitis and vascular inflam-
mation may have been underestimated, as no washout
medication period was required prior to study enrollment.
However, it is remarkable that, though many of the Pso
and PsA patients were undergoing treatment to mitigate
their inflammatory disease and/or CVD risk factors, we
found that sacroiliitis and vascular inflammation were still
readily detectible.
Despite these limitations, our data implicate sacroiliitis
as a significant and novel marker of increased CVD risk
in PsA. Further, FDG-PET/CT may hold promise to im-
prove CVD risk estimation as well as to delineate tissue
inflammation in the rheumatic diseases. The PACI study
(ClinicalTrials.gov Identifier: NCT01778569) is uniquely
poised to address these questions, as it includes a large,
ongoing, longitudinal cohort in which serial FDG-PET/
CT scans will be utilized to detect incident sacroiliitis
and CVD in Pso and PsA patients. Additional studies
are needed to substantiate and expand our present find-
ings, to link them to clinical prognoses and to understand
the effects of treatment on tissue-specific inflammation in
Pso and PsA patients.
Conclusion
Sacroiliitis is associated with increased vascular inflam-
mation beyond traditional CVD risk factors, suggesting
that sacroiliitis may identify patients at greater risk for
vascular complications.
Additional files
Additional file 1: Table S1. Aortic vascular inflammation is greater in
patients with the highest grade sacroiliitis. These data demonstrate that
those patients with definitive sacroiliitis on CT scan demonstrate greater
vascular inflammation by FDG-PET/CT compared to patients with suspected
or no sacroiliac disease.
Additional file 2: Table S2. Correlation analysis of aortic vascular
inflammation with clinical measures by subgroup. These data demonstrate
that cardiovascular risk factors, sacroiliitis by CT scan and psoriatic arthritis
are independently associated with vascular inflammation by FDG-PET/CT.
Additional file 3: Table S3. Sacroiliitis and psoriatic arthritis are
positively related to vascular inflammation even after adjustment for
cardiovascular disease risk factors and the markers of systemic
inflammation ESR and CRP. These data demonstrate that sacroiliitis by CT
scan and psoriatic arthritis are associated with vascular inflammation by
FDG-PET/CT beyond traditional cardiovascular risk factors and circulating
markers of systemic inflammation.
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